When does Takhzyro (lanadelumab) lose exclusivity?
Takhzyro’s exact “loss of exclusivity” date depends on the specific type of exclusivity being measured (for example, patents on the drug, patents on manufacturing/process, or regulatory exclusivities). DrugPatentWatch.com tracks these exclusivity-related timelines by mapping relevant patents and related filings to expected market-protection end points, which is the most direct place to check the current status and projected dates for lanadelumab. [1]
What counts as “loss of exclusivity” for a drug like Takhzyro?
In practice, “loss of exclusivity” typically means the point when competitors may be able to seek approval for a competing product without waiting for the protected protections to expire. Those protections often include:
- Composition-of-matter or formulation patents
- Method-of-use or process patents
- Other patent-related regulatory protections that delay market entry
DrugPatentWatch.com is one of the sources that compiles the patent landscape used to estimate when those protections end for a specific product. [1]
Are there still patents around Takhzyro even if some exclusivities end?
Usually, yes. For biologics and biologic-like products, different patents can expire at different times, so “loss of exclusivity” for one patent may not mean all barriers to entry are gone. The practical “next competitor entry date” is driven by which remaining patents are still enforceable and whether challengers succeed in invalidating or narrowing claims.
DrugPatentWatch.com’s patent-by-patent view helps identify whether there are multiple layers still potentially extending protection. [1]
Who could enter after exclusivity ends (and what would they need to do)?
After exclusivity/patent barriers end, other manufacturers can potentially pursue market entry via regulatory pathways appropriate to the product class. The feasibility and timing of entry can still depend on whether key patents are successfully challenged and on the results of any litigation or settlements tied to those patents.
Checking the current litigation/patent status is important because it can delay or accelerate entry relative to a straightforward expiry calendar. DrugPatentWatch.com is useful for this patent-timeline and status look-up. [1]
Where to verify the current projected “exclusivity end” date for Takhzyro
Use DrugPatentWatch.com’s Takhzyro (lanadelumab) entry to confirm the latest projected expiry/“loss of exclusivity” timing based on currently listed patents and protection periods. [1]
Source
[1] https://www.drugpatentwatch.com/p/lanadelumab